| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹3 0% | 2500% |
| - | - | 4,500 | ₹40 0% | 1250% |
| - | - | 4,700 | ₹5 0% | 1,1250% |
| - | - | 4,800 | ₹2 -43.66% | 5,7502.22% |
| - | - | 4,850 | ₹12.5 0% | 00% |
| - | - | 4,900 | ₹4.5 0% | 9,2500% |
| 1,875-6.25% | ₹567 68.49% | 5,000 | ₹3.5 0% | 10,250-2.38% |
| - | - | 5,050 | ₹8.55 0% | 00% |
| 6250% | ₹244.45 0% | 5,100 | ₹6.2 0% | 11,7500% |
| 6250% | ₹203.7 0% | 5,150 | ₹7.15 0% | 4,0000% |
| 3,8750% | ₹334.35 0% | 5,200 | ₹5.75 -38.5% | 24,125-11.05% |
| 1,5000% | ₹283 0% | 5,250 | ₹8.45 -36.94% | 8,2508.19% |
| 9,500-20% | ₹260.3 13.74% | 5,300 | ₹12.2 -35.1% | 18,625-23.19% |
| 4,8750% | ₹178 0% | 5,350 | ₹17.55 -34.75% | 23,62543.18% |
| 23,5000% | ₹185.05 25.41% | 5,400 | ₹23.25 -40.83% | 36,50025.86% |
| 10,125-2.40% | ₹144.25 33.25% | 5,450 | ₹35.25 -34.96% | 10,0000% |
| 73,125-10.13% | ₹112 32.54% | 5,500 | ₹49.05 -36.29% | 44,62559.37% |
| 36,375122.13% | ₹80.95 31.3% | 5,550 | ₹69.1 -33.65% | 6,75063.63% |
| 43,12523.65% | ₹59.3 32.95% | 5,600 | ₹95 -32.69% | 17,0006.25% |
| 6,000108.69% | ₹40.25 31.75% | 5,650 | - | - |
| 58,5001.73% | ₹27.5 22.76% | 5,700 | ₹209.55 0% | 1250% |
| 26,50098.13% | ₹18.65 24.33% | 5,750 | ₹237.45 0% | 1250% |
| 29,7502.14% | ₹12.75 8.97% | 5,800 | ₹300.5 0% | 5000% |
| 6,250-13.79% | ₹6.3 -11.88% | 5,900 | ₹388.55 0% | 2500% |
| 21,25036% | ₹4.7 2.17% | 6,000 | - | - |
| 2,2500% | ₹1.25 0% | 6,100 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
